|
||
![]() |
![]() |
|
| Home | About | Donate/Volunteer | Contact | Jobs| |
|
December 18, 2006Eli Lilly Said to Have Down-played Zyprexa Diabetes RisksRead more... Schizophrenia Med Side-effects
· Schizophrenia Medications
The New York Times reported this past weekend that "Indianapolis-based drug maker Eli Lilly and Co. has engaged in a decadelong effort to downplay the health risks of Zyprexa, its best-selling medication for schizophrenia, according to hundreds of internal Lilly documents and e-mail messages among top managers. The documents, given to The New York Times by a lawyer representing mentally ill patients, show Lilly executives kept important information from doctors about Zyprexa's links to obesity and its tendency to raise blood sugar -- known risk factors for diabetes.
Eli Lilly Responded to the NY Times article in the following prepared news release: Statement from Eli Lilly and Company: Response to The New York Times Article from December 17, 2006 Note: The Eli Lilly Internal memos and documents are available for your download and viewing here. Additional reading on this story CommentsPost a comment |
|
I gained 20 pounds in two weeks on Zyprexa.
Posted by: Uncle Sam at December 19, 2006 07:58 AM
That was not a bright move on their part. At all. Lilly is I think in financial trouble already, I think from a merger that didn't go well if I recall; this won't help their cause at all.
Thing is, the issue was very obvious regardless from the start. Alot of people don't gain weight on it and that's fine, about 2/3 don't (66%). However, those who do gain weight just simply switch to something else anyway, so why not share the documentation and look a lot better in the public eye? Dumb.
Posted by: slc2 at December 20, 2006 08:01 AM